At Increased Cost, Robotic Partial Nephrectomy Improves Kidney Cancer Outcomes

Article

A study found that robotic partial nephrectomy to remove kidney cancer tumors resulted in better outcomes, but also had significantly higher hospital charges. The data were presented at the annual meeting of the American Urological Association.

The use of robotic partial nephrectomy to remove kidney cancer tumors has increased in recent years, becoming more commonly used than open or laparoscopic partial nephrectomy and resulting in better outcomes. However, data from a study presented at the American Urological Association Annual Meeting also showed that the procedure is associated with significantly higher hospital charges as well.

Histopathologic image of clear cell carcinoma of the kidney; nephrectomy specimen; source: KGH, Wikimedia Commons

“This is the first analysis of robotic kidney surgery within the United States using a large federally held database and is therefore representative of broad practices,” said Khurshid R. Ghani, MD, of Vattikuti Urology Institute. “We have shown that there has been a dramatic uptake of robotic partial nephrectomy throughout the country, and it is now more popular than the laparoscopic approach.”

Although the use of partial nephrectomy has been increasing, research had not yet shown conclusively that it is a better operation than the traditional open or laparoscopic approaches.

Dr. Ghani and colleagues used data from the Nationwide Inpatient Sample from October 2008 to December 2010 to identify all patients who underwent open partial nephrectomy, laparoscopic partial nephrectomy, or robotic partial nephrectomy. Data were examined for practice patterns and perioperative outcomes.

Specifically, of 38,064 partial nephrectomies during the study period, 66.9% were open, 9.2% were laparoscopic, and 23.9% were robotic. In 2010, the relative increase in utilization of robotic partial nephrectomy was 45.4%, compared with 7.9% for open and 6.1% for laparoscopic. 

“More importantly, compared to open or laparoscopic partial nephrectomy, robotic partial nephrectomy had much lower complications,” Dr. Ghani told Cancer Network.

Patients who underwent either minimally invasive procedure had significantly reduced odds of receiving a blood transfusion (robotic, OR = 0.56, P < .001; laparoscopic, OR = 0.68, P = .016), postoperative complication (robotic, OR = 0.63, P < .001; laparoscopic OR = 0.78, P < .009), or experience a prolonged length of stay (robotic, OR = 0.27, P < .001; laparoscopic, OR = 0.41, P < .001).

In addition, a robotic procedure resulted in a reduced risk for intraoperative complications.

However, robotic kidney surgery costs more than the other two operations.

“It is likely that robotic kidney surgery will now become the predominant method to remove kidney tumors in the United States,” Dr. Ghani said. “Recently, there has been some negative press coverage on robotic kidney surgery, especially after a large study reported on outcomes after robotic hysterectomy. Our study shows robotic kidney surgery is safe and comparable, if not superior.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content